Targeting both IL-10 and CSF-1R with a bifunctional antibody has led to an expected reduction in tumor-associated macrophages and has also stimulated the proliferation, activation, and metabolic reprogramming of CD8+ T-cells, showing significant anti-tumor activity in various cancer models, particularly in head and neck cancer [104]. This evidence concerns the gene CD8A and neoplasm.